A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2013
At a glance
- Drugs TZP 102 (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Acronyms DIGEST
- 31 Aug 2018 Biomarkers information updated
- 17 Dec 2012 Status changed from recruiting to discontinued, as reported in a Tranzyme Pharma media release.
- 15 Nov 2012 Top line results for DIGEST are anticipated in the first half of 2013, according to a Tranzyme Pharma media release.